JP MORGAN/PUT/MODERNA/135/0.1/17.01.25 | Market Closed - Börse Stuttgart 20:50:02 28/06/2024 BST | ||
| 2.54 EUR | +5.39% |
|
| Current month | +55.83% | ||
| 1 month | +82.73% |
Comparison chart between the derivative product and it's underlying value
End-of-day quotes
Chart
MODERNA, INC.
Latest news about MODERNA, INC.
| Date | Price | Change |
|---|---|---|
| 28/06/24 | 2.54 | +5.39% |
| 27/06/24 | 2.41 | +2.12% |
| 26/06/24 | 2.36 | +34.09% |
| 25/06/24 | 1.76 | -1.12% |
| 24/06/24 | 1.78 | -6.81% |
Delayed Quote Börse Stuttgart
Last update June 28, 2024 at 08:50 pm
More quotesStatic data
| Product type | Plain-Vanilla-Warrants |
|---|---|
| Buy / Sell | PUT |
| Underlying | MODERNA, INC. |
| Issuer | J.P. Morgan |
| WKN | JL0U41 |
| ISIN | DE000JL0U419 |
| Date issued | 12/04/2023 |
| Strike | 135 $ |
| Maturity | 17/01/2025 (202 Days) |
| Parity | 10 : 1 |
| Emission price | 2.43 € |
| Emission volume | N/A |
| Settlement | cash |
| Currency | EUR |
Technical Indicators
| Highest since issue | 6.8 € |
|---|---|
| Lowest since issue | 1.07 € |
| Spread | 0.06 € |
| Spread % | 2.31% |
Company Profile
Moderna, Inc. is a biotechnology company specialized in research and development of therapeutics and vaccines for cancer, infectious, autoimmune and cardiovascular diseases. Net sales break down by type of revenue as follows:
- revenue from product sales (95.7%) ;
- revenues from grants (4%);
- revenues from collaboration agreements (0.3%).
At the end of 2021, the group possessed a portfolio of 15 products in clinical development, of which 3 in phase III, 8 in phase II and 4 in phase I, and 12 products in preclinical development.
Net sales are distributed geographically as follows: the United States (33.4%), Europe (37.1%) and other (29.5%).
Sector
-
Consensus: Moderna, Inc.
Sell
Buy
Mean consensus
OUTPERFORM
Number of Analysts
24
Last Close Price
118.8
USD
Average target price
145.9
USD
Spread / Average Target
+22.82%
- Stock Market
- Warrants
- Warrant
